Vertex Pharmaceuticals (VRTX) SEC Filings: History & Chart

Vertex Pharmaceuticals Incorporated (VRTX)VRTXVertex Pharmaceuticals Incorporated

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA

6,400 employees

www.vrtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Reshma Kewalramani

View full financials

Form	Filing Date	Accepted	Document
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 7, 2026	Jul 7, 2026	View filing
4	Jul 7, 2026	Jul 7, 2026	View filing
8-K	Jul 7, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	May 19, 2026	May 19, 2026	View filing
4	May 19, 2026	May 19, 2026	View filing
4	May 14, 2026	May 14, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8 POS	May 13, 2026	May 13, 2026	View filing
S-8	May 13, 2026	May 13, 2026	View filing
8-K	May 13, 2026	May 13, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing

SEC Filings

Recent Filings